Positive News SentimentPositive NewsNASDAQ:PLUR Pluri (PLUR) Stock Price, News & Analysis $4.24 -0.11 (-2.41%) Closing price 10/17/2025 03:56 PM EasternExtended Trading$4.46 +0.21 (+4.95%) As of 10/17/2025 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Pluri Stock (NASDAQ:PLUR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Pluri alerts:Sign Up Key Stats Today's Range$4.25▼$4.3450-Day Range$4.25▼$5.6852-Week Range$3.33▼$7.13Volume2,215 shsAverage Volume9,402 shsMarket Capitalization$34.64 millionP/E RatioN/ADividend YieldN/APrice Target$12.00Consensus RatingHold Company Overview Pluri (NASDAQ:PLUR) is a clinical-stage biotechnology company focused on the development and manufacturing of placental-derived cell therapy products. The company’s proprietary three-dimensional microcarrier expansion platform enables large-scale, off-the-shelf production of PLX (placental expanded) cells, which are being investigated for a range of acute and chronic conditions. Pluri’s approach seeks to combine the regenerative and immunomodulatory properties of stromal cells with a scalable manufacturing process that does not require patient-specific cell harvesting. Pluri advances its pipeline through internally funded research programs and strategic collaborations with academic institutions and government agencies. Its PLX cell therapies have been evaluated in clinical studies targeting critical limb ischemia, hematopoietic support following radiation exposure and tissue repair in musculoskeletal injuries. The company has also received grant funding for programs addressing acute radiation syndrome and continues to explore additional indications in immune and inflammatory diseases. Headquartered in Haifa, Israel, Pluri operates a GMP-certified manufacturing facility capable of supporting commercial-scale production. The company’s global footprint extends to clinical trial sites and partnership agreements in the United States, Europe and the Asia-Pacific region. Pluri’s leadership team brings extensive expertise in regenerative medicine, cellular manufacturing and regulatory affairs as it works toward potential market authorization and broad clinical adoption of its cell therapy products.AI Generated. May Contain Errors. Read More Pluri Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScorePLUR MarketRank™: Pluri scored higher than 48% of companies evaluated by MarketBeat, and ranked 572nd out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingPluri has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialPluri has a consensus price target of $12.00, representing about 182.7% upside from its current price of $4.25.Amount of Analyst CoveragePluri has only been the subject of 1 research reports in the past 90 days.Read more about Pluri's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Pluri is -0.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pluri is -0.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.55% of the float of Pluri has been sold short.Short Interest Ratio / Days to CoverPluri has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pluri has recently decreased by 2.99%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPluri does not currently pay a dividend.Dividend GrowthPluri does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.55% of the float of Pluri has been sold short.Short Interest Ratio / Days to CoverPluri has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pluri has recently decreased by 2.99%, indicating that investor sentiment is improving. News and Social Media3.2 / 5News SentimentN/A News SentimentPluri has a news sentiment score of 1.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Pluri this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for PLUR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added Pluri to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Pluri insiders have not sold or bought any company stock.Percentage Held by Insiders25.93% of the stock of Pluri is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 16.59% of the stock of Pluri is held by institutions.Read more about Pluri's insider trading history. Receive PLUR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pluri and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PLUR Stock News HeadlinesPluri Approves Equity Awards for CEO Yaky YanayOctober 16 at 5:30 PM | tipranks.comPluri subsidiary Coffeesai announces strategic collaboration for manufacturingOctober 8, 2025 | msn.comINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.October 19 at 2:00 AM | Traders Agency (Ad)Pluri Subsidiary Coffeesai and Instituto del Café de Chiapas Announce Strategic Collaboration to Advance Cell-Based Coffee Manufacturing in MexicoOctober 8, 2025 | markets.businessinsider.comPluri files to sell 3.425M common shares for holdersSeptember 17, 2025 | msn.comPluri Resolves Nasdaq Compliance Issue with New DirectorSeptember 12, 2025 | tipranks.comPluri Appoints Eitan Ajchenbaum to Board of DirectorsSeptember 11, 2025 | tipranks.comPluri Inc. director not re-elected, Nasdaq compliance cure period grantedJuly 5, 2025 | investing.comSee More Headlines PLUR Stock Analysis - Frequently Asked Questions How have PLUR shares performed this year? Pluri's stock was trading at $4.28 at the beginning of the year. Since then, PLUR stock has decreased by 0.8% and is now trading at $4.2450. How were Pluri's earnings last quarter? Pluri Inc. (NASDAQ:PLUR) announced its quarterly earnings data on Wednesday, September, 17th. The company reported ($2.62) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.73) by $1.89. The firm earned $0.91 million during the quarter, compared to analyst estimates of $0.40 million. Pluri had a negative trailing twelve-month return on equity of 4,191.91% and a negative net margin of 1,701.19%. When did Pluri's stock split? Pluri's stock reverse split on Monday, April 1st 2024.The 1-8 reverse split was announced on Monday, April 1st 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. How do I buy shares of Pluri? Shares of PLUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Pluri own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pluri investors own include Digital Turbine (APPS), Lightning eMotors (ZEV), Archer Aviation (ACHR), ChargePoint (CHPT) and Canoo (GOEV). Company Calendar Last Earnings9/17/2025Today10/19/2025Fiscal Year End6/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PLUR CIK1158780 Webpluri-biotech.com Phone972747108600Fax972-74-710-8787Employees150Year FoundedN/APrice Target and Rating Average Price Target for Pluri$12.00 High Price Target$12.00 Low Price Target$12.00 Potential Upside/Downside+182.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($5.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$22.58 million Net Margins-1,701.19% Pretax Margin-1,740.64% Return on Equity-4,191.91% Return on Assets-88.27% Debt Debt-to-Equity Ratio51.65 Current Ratio0.68 Quick Ratio0.68 Sales & Book Value Annual Sales$1.34 million Price / Sales25.85 Cash FlowN/A Price / Cash FlowN/A Book Value($0.11) per share Price / Book-38.59Miscellaneous Outstanding Shares8,160,000Free Float6,041,000Market Cap$34.64 million OptionableOptionable Beta0.66 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:PLUR) was last updated on 10/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pluri Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pluri With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.